NASDAQ:EPZM Epizyme (EPZM) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free EPZM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.47▼$1.4750-Day Range$1.47▼$1.5252-Week Range$0.41▼$5.80Volume7,960 shsAverage Volume3.23 million shsMarket Capitalization$247.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Epizyme alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Epizyme Stock (NASDAQ:EPZM)Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. EPZM Stock News HeadlinesNovember 1, 2023 | morningstar.combluebird bio Inc BLUEMarch 22, 2023 | thestreet.comCelgene, Jounce Therapeutics in Early Cancer Immunotherapy Development PactMay 6, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).August 12, 2022 | nasdaq.comAptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal - NasdaqAugust 12, 2022 | streetinsider.comForm SC 14D9/A Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comAugust 10, 2022 | finance.yahoo.comThe past five years for Epizyme (NASDAQ:EPZM) investors has not been profitableAugust 9, 2022 | benzinga.comEpizyme: Q2 Earnings Insights - BenzingaAugust 9, 2022 | businesswire.comEpizyme Reports Second Quarter 2022 Financial Results and Provides Business Update - Business WireMay 6, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).August 9, 2022 | apnews.comEpizyme: Q2 Earnings SnapshotAugust 5, 2022 | seekingalpha.comIpsen extends tender offer date in Epizyme deal to get US antitrust clearance - Seeking AlphaAugust 5, 2022 | businesswire.comIpsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 - Business WireJuly 28, 2022 | finance.yahoo.comIpsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance - Yahoo FinanceJuly 26, 2022 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, EPZM, LION - PR NewswireJuly 16, 2022 | benzinga.comShareholder Alert - The M&A Class Action Firm Continues Investigating the Merger - FSTX, EPZM, STCN, SIMO - BenzingaJuly 14, 2022 | prnewswire.comSHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations - PR NewswireJuly 14, 2022 | benzinga.comEPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM - BenzingaJuly 13, 2022 | streetinsider.comForm SC 14D9 Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comJuly 11, 2022 | gurufocus.comEPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - GuruFocus.comJuly 10, 2022 | globenewswire.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, RADA, EPZM - GlobeNewswireJuly 6, 2022 | prnewswire.comMoore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm - PR NewswireJuly 6, 2022 | seekingalpha.comEpizyme Acquisition By Ipsen: CVR Value (NASDAQ:EPZM) - Seeking AlphaJuly 5, 2022 | prnewswire.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, USAK, EPZM - PR NewswireJuly 5, 2022 | marketscreener.comEpizyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.comJuly 1, 2022 | streetinsider.comEPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - StreetInsider.comJuly 1, 2022 | benzinga.comEPIZYME ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of EPZM and Encourages Investors to Contact the FirmJune 29, 2022 | gurufocus.comEPIZYME INVESTOR ALERT by the - GuruFocus.comSee More Headlines Receive EPZM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EPZM CUSIPN/A CIK1571498 Webwww.epizyme.com Phone(617) 229-5872Fax617-349-0707Employees250Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-251,120,000.00 Net Margins-391.90% Pretax Margin-391.80% Return on Equity-2,459.33% Return on Assets-69.74% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.19 Sales & Book Value Annual Sales$37.43 million Price / Sales6.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.54) per share Price / Book-2.72Miscellaneous Outstanding Shares168,329,000Free Float128,968,000Market Cap$247.44 million OptionableOptionable Beta-0.41 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Grant C. Bogle (Age 64)Pres, CEO, Principal Financial Officer & Director Comp: $923.32kDr. Jeffery L. Kutok M.D. (Age 55)Ph.D., Chief Scientific Officer Comp: $646.13kDr. H. Robert HorvitzCo-Founder & Chairman of the Scientific Advisory BoardDr. Yi ZhangScientific Co-Founder & Member of The Scientific Advisory BoardMr. Jerald Korn J.D. (Age 43)Chief Operating Officer Mr. Joseph Beaulieu (Age 41)Sr. VP, Head of Fin., Controller, Treasurer & Principal Accounting Officer Mr. Craig West CFAVP of Investor RelationsMr. John F. Weidenbruch (Age 61)Sr. VP, Gen. Counsel & Sec. Ms. Tanja WeberChief Bus. OfficerDr. Mark A. De Rosch Ph.D. (Age 58)Chief Regulatory Officer More ExecutivesKey CompetitorsAquestive TherapeuticsNASDAQ:AQSTAC ImmuneNASDAQ:ACIUPuma BiotechnologyNASDAQ:PBYI23andMeNASDAQ:MEVerastemNASDAQ:VSTMView All Competitors EPZM Stock Analysis - Frequently Asked Questions How were Epizyme's earnings last quarter? Epizyme, Inc. (NASDAQ:EPZM) announced its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.16. The biopharmaceutical company had revenue of $5.20 million for the quarter, compared to analyst estimates of $8.65 million. Epizyme had a negative net margin of 391.90% and a negative trailing twelve-month return on equity of 2,459.33%. The business's revenue for the quarter was up 45.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.55) earnings per share. What other stocks do shareholders of Epizyme own? Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Pfizer (PFE), Micron Technology (MU), Novavax (NVAX), CRISPR Therapeutics (CRSP), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX). This page (NASDAQ:EPZM) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epizyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
